Ascidian and Lilly Sign $1.9B Kidney Disease RNA Deal
BOSTON, Massachusetts, USA, June 3, 2026 Ascidian Therapeutics and Eli Lilly and Company have entered into a landmark global...
kidney disease
Advertisement
Roche’s Gazyva Moves Closer to Public Access in Canada for Lupus Nephritis
MISSISSAUGA, Ontario, May 22, 2026 Roche Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive reimbursement recommendation...
Arch Biopartners Advances Phase II AKI Trial
TORONTO, May 22, 2026 Arch Biopartners announced that Royal Columbian Hospital (RCH) in British Columbia has dosed its first...
ArteraAI Breast Gains FDA Clearance for Cancer Risk
SAN FRANCISCO, May 6, 2026 Artera announced that the U.S. Food and Drug Administration (FDA) has granted clearance for...
GSK Signs $1B SiranBio siRNA Cardiometabolic Deal
SUZHOU, China, May 6, 2026 SiranBio announced a major global licensing agreement with GSK for its investigational siRNA therapeutic...
Advertisements
AstraZeneca’s Ultomiris Shows Phase 3 Breakthrough in IgAN
Cambridge, United Kingdom – April 21, 2026 AstraZeneca announced that its complement inhibitor Ultomiris® (ravulizumab) achieved statistically significant and...
Akebia Therapeutics Doses First in AKB-9090 Trial
CAMBRIDGE, Mass., April 13, 2026 Akebia Therapeutics, Inc., a biopharmaceutical company focused on kidney disease, has announced that the...
FibroBiologics Advances Thymus Organoid Cancer Therapy
HOUSTON, Texas | April 10, 2026 FibroBiologics has unveiled promising preclinical data for its novel thymus organoid platform, demonstrating...
Sobi Gains Canada Approval for EMPAVELI Kidney Drug
WALTHAM, Massachusetts | April 9, 2026 Swedish Orphan Biovitrum (Sobi) has announced that Health Canada has approved EMPAVELI® (pegcetacoplan),...
Apecotrep Shows 40% Proteinuria Reduction in Phase II FSGS Trial
Ingelheim, Germany | January 29, 2026 — Boehringer Ingelheim announced positive results from a 12-week Phase II clinical trial...
Advertisement
